Increasingly, patients are able to receive parenteral medicines at home rather than in the hospital setting. We describe our approach to setting up a new intravenous zoledronic acid homecare service for patients with osteoporosis. Initial evaluation of service feasibility demonstrated a marginal cost saving of approximately 6%, when the drug is administered via homecare compared with hospital day-case unit. Rigorous risk assessment was conducted prior to service initiation. Implementation strategies are outlined. Surveys confirmed that the majority of patients were highly satisfied with the home infusion service.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.